CN106540143A - A kind of pharmaceutical composition and purposes for treating lymphatic cancer - Google Patents
A kind of pharmaceutical composition and purposes for treating lymphatic cancer Download PDFInfo
- Publication number
- CN106540143A CN106540143A CN201710069237.9A CN201710069237A CN106540143A CN 106540143 A CN106540143 A CN 106540143A CN 201710069237 A CN201710069237 A CN 201710069237A CN 106540143 A CN106540143 A CN 106540143A
- Authority
- CN
- China
- Prior art keywords
- rhizoma
- parts
- pharmaceutical composition
- fen
- rhizoma atractylodis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a kind of medical composition and its use for treating lymphatic cancer, described pharmaceutical composition by the Radix Pulsatillae, Spica Prunellae, Rhizoma Atractylodis, the Rhizoma Atractylodis Macrocephalae, Poria, Polyporus, Rhizoma Alismatis, Pericarpium Citri Reticulatae, Rhizoma dioscoreae, Seem Lablab Album, fry Semen Coicis, Radix Glycyrrhizae, Pulvis Talci, Rhizoma Dioscoreae Septemlobae He Herba Polygoni Avicularis are constituted.The pharmaceutical composition of the present invention has functions that to treat lymphatic cancer and improves weight in patients, has broad prospects in terms of curative drug and health product.
Description
Technical field
The present invention relates to technical field of Chinese medicine, more particularly to a kind of pharmaceutical composition and use for treating lymphatic cancer
On the way.
Background technology
1. lymphatic cancer
Malignant lymphoma is to be primary in lymph node or other adenoid malignant tumor, is China also known as " lymphoma "
One of ten common big malignant tumor.During primary disease is more common in, it is young, male patient is more than women.Primary disease is by its cell component
Difference can be divided into two big class of Hokdkin disease and non_hodgkin lymphoma.Its grade malignancy differs, by one histiocyte of lymph
Caused by system neoplasm, mostly occur in cervical lymph node.
The performance of malignant lymphoma mainly touches the lymph node of enlargement on body, and early stage is all superficial, therefore often
Ignored by people.About 60% lymphatic cancer finds the lymphadenectasis in cervical region first, the single enlargements of Kai Shi Shi Only, slowly then
Number increases, and more enlargement.Lymphatic cancer can betide total lymphoid tissue, nod as follows, lower jaw, forward neck portion, on clavicle, oxter,
Groin, indulges by diaphragm chamber or abdominal artery, then betides sometimes internal organs and cause pressure symptom；If betiding stomach, small intestinal or large intestine
The symptom of peptic ulcer or gastrointestinal dysfunction such as may then there is abdominal distention, have blood in stool, vomit, suffering from abdominal pain；If lymphoma invades bone marrow,
The general blood cell such as green around the gills, fever, abnormal bleeding may then be produced and reduce disease, sometimes the visible abnormal lymph in periphery blood
Ball occurs.
It is now recognized that lymphatic cancer is one of cancer with fastest developing speed.Patient with lymphatic cancer often just expands at short notice
Whole body is scattered to, thus with very poor treatment prognosis.Just because of this, traditional surgical removal means are for lymphatic cancer patient often
It is difficult to prove effective.
2. the tcm therapy of tumor
At present, doctor trained in Western medicine concentrates on two aspects to the therapy of tumor：Surgical removal and target administration and X-ray therapy
Associated methods.Surgical removal method has significant limitation, it is difficult to for the cancers such as lymphatic cancer, cerebroma or tumor class
Type.And target administration and X-ray therapy associated methods (abbreviation radiotherapy) can bring undesirable infringement to the body of patient.Therefore,
The relatively low medicine of research murder by poisoning degree, becomes what tumor research field personnel expected always.
Radix Pulsatillae medical material takes from the Ranunculaceae Pulsatilla plant Radix Pulsatillae (Pulsatillachinensis (Bunge)
Regel dry root), bitter in the mouth are cold in nature.Return stomach, large intestine channel, have heat-clearing and toxic substances removing, the work(of eliminating pathogenic heat from blood to cure dysentery.It is for toxic-heat and blood stasis, cloudy
Itch leukorrhagia, amebic dysentery.According to the literature, protoanemonin (Protoanemonin), Anemonin are contained in the Radix Pulsatillae
(Anemonin), Radix Pulsatillae spirit (Okinalin, C32H46O2), Radix Pulsatillae English (Okinalein, C4H6O2) etc., in recent years state
Inside and outside scholar goes out tens kinds of pentacyclic triterpene saponin compositions from isolation identification in Pulsatilla plant, and these saponin are mainly olive
Two kinds of alkane type and lupinane type.Cai Ying etc. have studied Radix Pulsatillae water extraction by cell counting, mtt assay, Colony forming experiment
The extracorporeal anti-tumor function of liquid and alcohol extract, shows that Aqueous extracts, alcohol extract have direct cytotoxicity, and with time, dosage are in
Positive correlation, and Aqueous extracts effect it is stronger than alcohol extract, show Radix Pulsatillae anti-tumor active ingredient system water-soluble substanceses, also can part it is molten
In ethanol.Clock Qiu etc. have studied the biological activity of the extracorporeal suppression tumor cell growth of pulchinenoside, find which to people liver
Cancer 7721, human cervical carcinoma HeLa growths have inhibitory action.Described in CN201010624796.X Chinese invention patent applications
Extract its saponin component from the Radix Pulsatillae, and using the saponin constituent carrying out the research of gastric cancer in nude mice test.
However, heavy dose of use can cause the just dilute many reaction of loss of appetite, laxation.Still lack the Radix Pulsatillae at present
Compatibility proved recipe, still can not realize preferable therapeutic effect using the Radix Pulsatillae and its extract merely.
The content of the invention
It is therefore an object of the present invention to a kind of pharmaceutical composition for treating lymphatic cancer is provided, and said composition exists
Treat lymphatic cancer, improve patient's body constitution and the purposes in survival condition.
In one aspect of the invention, there is provided a kind of pharmaceutical composition for treating lymphatic cancer, it is characterised in that institute
The pharmaceutical composition stated is by the Radix Pulsatillae, Spica Prunellae, Rhizoma Atractylodis, the Rhizoma Atractylodis Macrocephalae, Poria, Polyporus, Rhizoma Alismatis, Pericarpium Citri Reticulatae, Rhizoma dioscoreae, Seem Lablab Album, stir-fry
Semen Coicis, Radix Glycyrrhizae, Pulvis Talci, Rhizoma Dioscoreae Septemlobae are He Herba Polygoni Avicularis are constituted.
In currently preferred aspect, described pharmaceutical composition is by 1 part by weight of the Radix Pulsatillae, 0.8-1.2 part summers
Hay, 0.8-1.2 part Rhizoma Atractylodis, 0.8-1.2 part Rhizoma Atractylodis Macrocephalaes, 0.8-1.2 part Porias, 0.8-1.2 part Polyporus, 0.8-1.2 part Rhizoma Alismatis,
1.6-2.4 part Pericarpium Citri Reticulataes, 0.8-6.0 part Rhizoma dioscoreaes, 0.8-1.2 part Seem Lablab Albums, 2.4-7.2 parts fry Semen Coicis, 0.8-1.2 part Radix Glycyrrhizaes,
4.8-7.2 part Pulvis Talci, 0.8-1.2 Fen Rhizoma Dioscoreae Septemlobae and 0.8-1.2 Fen Herba Polygoni Avicularis are constituted.
In currently preferred aspect, described pharmaceutical composition by 1 part by weight the Radix Pulsatillae, 0.8 part of Spica Prunellae,
0.8 part of Rhizoma Atractylodis, 0.8 part of Rhizoma Atractylodis Macrocephalae, 0.8 portion of Poria, 0.8 portion of Polyporus, 0.8 portion of Rhizoma Alismatis, 2.4 parts of Pericarpium Citri Reticulataes, 1.2 parts of Rhizoma dioscoreaes, 1.2
Part Seem Lablab Album, 2.4 parts of stir-fry Semen Coicis, 0.8 part of Radix Glycyrrhizae, 4.8 parts of Pulvis Talci, 0.8 Fen Rhizoma Dioscoreae Septemlobae and 0.8 Fen Herba Polygoni Avicularis are constituted.
In currently preferred aspect, described pharmaceutical composition by 1 part by weight the Radix Pulsatillae, 0.8 part of Spica Prunellae,
0.8 part of Rhizoma Atractylodis, 0.8 part of Rhizoma Atractylodis Macrocephalae, 0.8 portion of Poria, 0.8 portion of Polyporus, 0.8 portion of Rhizoma Alismatis, 2.4 parts of Pericarpium Citri Reticulataes, 1.2 parts of Rhizoma dioscoreaes, 1.2
Part Seem Lablab Album, 7.2 parts of stir-fry Semen Coicis, 1.2 parts of Radix Glycyrrhizaes, 7.2 parts of Pulvis Talci, 1.2 Fen Rhizoma Dioscoreae Septemlobae and 1.2 Fen Herba Polygoni Avicularis are constituted.
In currently preferred aspect, described pharmaceutical composition by 1 part by weight the Radix Pulsatillae, 0.8 part of Spica Prunellae,
1.2 parts of Rhizoma Atractylodis, 0.8 part of Rhizoma Atractylodis Macrocephalae, 1.2 portions of Porias, 1.2 portions of Polyporus, 1.2 portions of Rhizoma Alismatis, 1.6 parts of Pericarpium Citri Reticulataes, 4.8 parts of Rhizoma dioscoreaes, 0.8
Part Seem Lablab Album, 2.4 parts of stir-fry Semen Coicis, 0.8 part of Radix Glycyrrhizae, 6.0 parts of Pulvis Talci, 0.8 Fen Rhizoma Dioscoreae Septemlobae and 1.2 Fen Herba Polygoni Avicularis are constituted.
In currently preferred aspect, described pharmaceutical composition by 1 part by weight the Radix Pulsatillae, 0.8 part of Spica Prunellae,
0.8 part of Rhizoma Atractylodis, 0.8 part of Rhizoma Atractylodis Macrocephalae, 0.8 portion of Poria, 0.8 portion of Polyporus, 0.8 portion of Rhizoma Alismatis, 2.4 parts of Pericarpium Citri Reticulataes, 6 parts of Rhizoma dioscoreaes, 1.2 parts
Seem Lablab Album, 7.2 parts of stir-fry Semen Coicis, 1.2 parts of Radix Glycyrrhizaes, 4.8 parts of Pulvis Talci, 1.2 Fen Rhizoma Dioscoreae Septemlobae and 0.8 Fen Herba Polygoni Avicularis are constituted.
In currently preferred aspect, described pharmaceutical composition by 1 part by weight the Radix Pulsatillae, 0.8 part of Spica Prunellae,
1.2 parts of Rhizoma Atractylodis, 0.8 part of Rhizoma Atractylodis Macrocephalae, 1.2 portions of Porias, 1.2 portions of Polyporus, 1.2 portions of Rhizoma Alismatis, 1.6 parts of Pericarpium Citri Reticulataes, 4.8 parts of Rhizoma dioscoreaes, 0.8
Part Seem Lablab Album, 6 parts of stir-fry Semen Coicis, 0.8 part of Radix Glycyrrhizae, 7.2 parts of Pulvis Talci, 0.8 Fen Rhizoma Dioscoreae Septemlobae and 0.8 Fen Herba Polygoni Avicularis are constituted.
In other aspects of the present invention, the pharmaceutical composition for additionally providing the above is used for treating the medicine of lymphatic cancer in preparation
In purposes.
In other aspects of the present invention, the pharmaceutical composition for additionally providing the above is being prepared for improving with lymphatic cancer
Purposes in the health product of the body constitution of experimenter.
The pharmaceutical composition of the present invention has functions that to treat lymphatic cancer and improves weight in patients, in curative drug and guarantor
Have broad prospects in terms of strong product.In pharmaceutical composition the matching somebody with somebody by regulating drug provided by currently preferred aspect
Than the technique effect of Liver and kidney toxicity reduction is realized on the basis of being treated using Rhizoma Alismatis.
Specific embodiment
Embodiment 1：Chinese medicine formula and fried
Carry out the pharmaceutical composition of test preparation group 1-5 according to the formula shown in table 1, the unit of quantity in table is gram.
Table 1：The formula of the pharmaceutical composition of the present invention：
The pharmaceutical composition constituted by Chinese medicine by more than is placed in terrine the medicine juice for being fried into 500 milliliters or so.Specifically
Decocting method is that Chinese medicine is placed in terrine, and addition there was not the water of 1-2 centimetre of medical material, and big fire is heated to seethe with excitement and switchs to small fire
Heating 30 minutes.After extracting medicine juice, add water repetition above step.It is final to obtain 500 milliliters or so of medicine juice.Unless additionally said
Bright, all of Chinese medicine is purchased from Tongrentang.
Embodiment 2：Drug effect animal experiment
Enter in mice body using people's Burkitt lymphoma cell strain Daudi Jing tail vein injections, it is little that lymphatic cancer is set up in exploration
Mouse model.Specific test method is found in《Chinese Journal of Cancer》,2009,28(2):217-220.Profit
6 groups of test mices are obtained with the method, 8 per group, the female mice of all ten week old (is injected in six week old, four
Zhou Houjin is exercised and is used).Mice to more than carries out the medication treatment of 1 course for the treatment of (15 days).The mode of medication is to use syringe
Oral perfusion is carried out to mice to feed, every morning 09:00 and 21:00 respectively perfusion feed once.
At pre-treatment and after treatment, the body weight of mice is measured respectively, and after the medication treatment period of mice terminates,
Kill mice and its molding lymphoma is extractd by surgical method, and weigh fresh lymphadenomatous weight.Table 2 shows
Effect of the medicament of the present invention to lymphatic cancer mice.
Table 2：Effect of the medicament of the present invention to lymphatic cancer mice
*：Test does not proceed to a course for the treatment of of 15 days.In the test group, mice starts death enter test the 7th day,
It is all dead to this group of mice when the 10th day.The data that the data are obtained when being dead mouse.
Data from more than, when the medicament of the present invention is given so that the life span of mice is obviously prolonged, and
The weight ratio experiment of mice is obviously improved before starting.At the same time, in group B-F, the tumor weight of mice is than A-B group
There is significantly reduction.As can be seen here, there is pharmaceutical composition of the invention prolongation lymphatic cancer to suffer from Mus life-time, improve its life
Bioplasm amount, mitigates the effect of its tumor weight.
Embodiment 3：Hepatotoxicity is tested
According to report, the feedstuff containing Rhizoma Alismatis extract is given to rat, can make the liver of rat become turbid swelling and
There is swelling, cavity in hyaline degeneration, Kidney anomaly.By the mice of each experimental group described by embodiment 2
After execution, dissect and obtain its liver, and observe the hyaline degeneration state of the swelling of its liver.As a result find, test group 4
Obvious liver swelling and hyaline degeneration state are not observed with 5 medicine, and in test group 3, occurs in that obvious liver
Swelling and hyaline degeneration phenomenon.Liver swelling and hyaline degeneration phenomenon in test group 1-2 is lighter, but exists conscientiously.
This shows when the Rhizoma Alismatis medication amount for using is improved have facilitation to the therapeutic effect of lymphatic cancer, but while also cause tight
The hepatotoxicity of weight, and cause liver serious change occur.Inventor very surprisingly it has been found that, at the same time using the stir-fry heart of a lotus seed of dosage
During the Rhizoma dioscoreae of Renhe, the hepatotoxicity caused by Rhizoma Alismatis in this prescription can be alleviated.As shown in the medicine of test group 5, while real
Rhizoma Alismatis (the namely lymphatic cancer therapeutic effect of high effect) and the hypotoxicity of high dose are showed, with preferably using prospect.
Embodiment 4：Body reconciles test
Six patients with lymphatic cancer are collected, this six lymphatic cancer patients are the cutaneous T cell lymphoma II phases and suffer from
Person, men and women are each three.This six lymphatic cancer patients were treated in 15 with each course for the treatment of, and used test group respectively
4th, 5 medicine.Every patient carries out two cycle therapy.Specific experiment result is as shown in table 3.Before patient is admitted to hospital and after being admitted to hospital
Carry out the chemical examination of 7 indexs of liver function.
Table 3：Body state table before and after the medication of six lymphatic cancer patients
Six patients have different degrees of body weight increase before and after medication, and its lymph cancerous symptom substantially mitigates.
This shows that patients have recovered in ailing torment, and body quality has also taken a turn for the better.Patient 2 is a middle school female religion
Teacher.She patient return visit in represent, after making a definite diagnosis with lymphatic cancer, confidence was lost to life once, was had lost all desire for food and drink, people
Day is gradually thin.Before the test organized by the present invention is participated in, body weight only has 42.5 kilograms.Take this medicine one month afterwards,
Feel that symptom takes an evident turn for the better, body weight is also increased, sleep takes an evident turn for the better.Patient 5 is a retired worker, is finding oneself
Long-term night sweat, body weight are gone to a doctor after unexpectedly mitigating for a long time and find to suffer from lymphatic cancer.Start after western medical treatment is invalid
With Chinese traditional treatment.Through the treatment of month, his body weight increase, and have a stomachache, the symptom of chronic diarrhea has and substantially subtracts
Gently.
Each embodiment above shows that each group Chinese medicine composition of the present invention has to lymphatic cancer significantly controls curative effect
Really.And by using the combination of Semen Coicis and Rhizoma dioscoreae is fried, alleviate the drug toxicity that principal agent imitates medicine Rhizoma Alismatis so that Huan Zheke
To receive treatment in the case where hepatotoxicity is not subject to.It was unexpectedly determined that exclusive use stir-fry Semen Coicis or Rhizoma dioscoreae are not
This Rhizoma Alismatis toxicity can be played a part of to be reduced.Both combinations reduce having positive effect for Rhizoma Alismatis toxicity, exist bright
Aobvious synergism.
Claims (9)
1. a kind of pharmaceutical composition for treating lymphatic cancer, it is characterised in that described pharmaceutical composition is withered by the Radix Pulsatillae, summer
Grass, Rhizoma Atractylodis, the Rhizoma Atractylodis Macrocephalae, Poria, Polyporus, Rhizoma Alismatis, Pericarpium Citri Reticulatae, Rhizoma dioscoreae, Seem Lablab Album, stir-fry Semen Coicis, Radix Glycyrrhizae, Pulvis Talci, Rhizoma Dioscoreae Septemlobae are He Herba Polygoni Avicularis
Constituted.
2. pharmaceutical composition according to claim 1, it is characterised in that described pharmaceutical composition is by 1 part by weight
The Radix Pulsatillae, 0.8-1.2 part Spica Prunellaes, 0.8-1.2 part Rhizoma Atractylodis, 0.8-1.2 part Rhizoma Atractylodis Macrocephalaes, 0.8-1.2 part Porias, 0.8-1.2
Part Polyporus, 0.8-1.2 part Rhizoma Alismatis, 1.6-2.4 part Pericarpium Citri Reticulataes, 0.8-6.0 part Rhizoma dioscoreaes, 0.8-1.2 part Seem Lablab Albums, the stir-fry of 2.4-7.2
Semen Coicis, 0.8-1.2 part Radix Glycyrrhizaes, 4.8-7.2 part Pulvis Talci, 0.8-1.2 Fen Rhizoma Dioscoreae Septemlobae and 0.8-1.2 Fen Herba Polygoni Avicularis are constituted.
3. pharmaceutical composition according to claim 2, it is characterised in that described pharmaceutical composition is by 1 part by weight
The Radix Pulsatillae, 0.8 part of Spica Prunellae, 0.8 part of Rhizoma Atractylodis, 0.8 part of Rhizoma Atractylodis Macrocephalae, 0.8 portion of Poria, 0.8 portion of Polyporus, 0.8 portion of Rhizoma Alismatis, 2.4
Part Pericarpium Citri Reticulatae, 1.2 parts of Rhizoma dioscoreaes, 1.2 parts of Seem Lablab Albums, 2.4 parts of stir-fry Semen Coicis, 0.8 part of Radix Glycyrrhizae, 4.8 parts of Pulvis Talci, 0.8 Fen Rhizoma Dioscoreae Septemlobae and 0.8
Fen Herba Polygoni Avicularis are constituted.
4. pharmaceutical composition according to claim 2, it is characterised in that described pharmaceutical composition is by 1 part by weight
The Radix Pulsatillae, 0.8 part of Spica Prunellae, 0.8 part of Rhizoma Atractylodis, 0.8 part of Rhizoma Atractylodis Macrocephalae, 0.8 portion of Poria, 0.8 portion of Polyporus, 0.8 portion of Rhizoma Alismatis, 2.4
Part Pericarpium Citri Reticulatae, 1.2 parts of Rhizoma dioscoreaes, 1.2 parts of Seem Lablab Albums, 7.2 parts of stir-fry Semen Coicis, 1.2 parts of Radix Glycyrrhizaes, 7.2 parts of Pulvis Talci, 1.2 Fen Rhizoma Dioscoreae Septemlobae and 1.2
Fen Herba Polygoni Avicularis are constituted.
5. pharmaceutical composition according to claim 2, it is characterised in that described pharmaceutical composition is by 1 part by weight
The Radix Pulsatillae, 0.8 part of Spica Prunellae, 1.2 parts of Rhizoma Atractylodis, 0.8 part of Rhizoma Atractylodis Macrocephalae, 1.2 portions of Porias, 1.2 portions of Polyporus, 1.2 portions of Rhizoma Alismatis, 1.6
Part Pericarpium Citri Reticulatae, 4.8 parts of Rhizoma dioscoreaes, 0.8 part of Seem Lablab Album, 2.4 parts of stir-fry Semen Coicis, 0.8 part of Radix Glycyrrhizae, 6.0 parts of Pulvis Talci, 0.8 Fen Rhizoma Dioscoreae Septemlobae and 1.2
Fen Herba Polygoni Avicularis are constituted.
6. pharmaceutical composition according to claim 2, it is characterised in that described pharmaceutical composition is by 1 part by weight
The Radix Pulsatillae, 0.8 part of Spica Prunellae, 0.8 part of Rhizoma Atractylodis, 0.8 part of Rhizoma Atractylodis Macrocephalae, 0.8 portion of Poria, 0.8 portion of Polyporus, 0.8 portion of Rhizoma Alismatis, 2.4
Part Pericarpium Citri Reticulatae, 6 parts of Rhizoma dioscoreaes, 1.2 portions of Seem Lablab Albums, 7.2 parts fry Semen Coicis into, 1.2 parts of Radix Glycyrrhizaes, 4.8 parts of Pulvis Talci, 1.2 Fen Rhizoma Dioscoreae Septemlobae and 0.8
Fen Herba Polygoni Avicularis are constituted.
7. pharmaceutical composition according to claim 2, it is characterised in that described pharmaceutical composition is by 1 part by weight
The Radix Pulsatillae, 0.8 part of Spica Prunellae, 1.2 parts of Rhizoma Atractylodis, 0.8 part of Rhizoma Atractylodis Macrocephalae, 1.2 portions of Porias, 1.2 portions of Polyporus, 1.2 portions of Rhizoma Alismatis, 1.6
Part Pericarpium Citri Reticulatae, 4.8 parts of Rhizoma dioscoreaes, 0.8 portion of Seem Lablab Album, 6 parts fry Semen Coicis, 0.8 portion of Radix Glycyrrhizae, 7.2 parts of Pulvis Talci, 0.8 Fen Rhizoma Dioscoreae Septemlobae and 0.8 part
Herba Polygoni Avicularis are constituted.
8. the purposes that the pharmaceutical composition any one of claim 1-7 is used in the medicine for treating lymphatic cancer in preparation.
9. the pharmaceutical composition any one of claim 1-7 is preparing the body for experimenter of the raising with lymphatic cancer
Purposes in the health product of matter.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710069237.9A CN106540143A (en) | 2017-02-08 | 2017-02-08 | A kind of pharmaceutical composition and purposes for treating lymphatic cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710069237.9A CN106540143A (en) | 2017-02-08 | 2017-02-08 | A kind of pharmaceutical composition and purposes for treating lymphatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106540143A true CN106540143A (en) | 2017-03-29 |
Family
ID=58398632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710069237.9A Pending CN106540143A (en) | 2017-02-08 | 2017-02-08 | A kind of pharmaceutical composition and purposes for treating lymphatic cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106540143A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103394067A (en) * | 2013-03-11 | 2013-11-20 | 肖鸣春 | Cancer treating pharmaceutical composition and preparation method thereof |
| CN104043057A (en) * | 2014-06-28 | 2014-09-17 | 王星月 | Traditional Chinese medicinal composition for treating lymph cancer |
| CN104173835A (en) * | 2014-09-03 | 2014-12-03 | 四川金堂海纳生物医药技术研究所 | Oral medicine for treating lymphangioma and preparation method of oral medicine |
-
2017
- 2017-02-08 CN CN201710069237.9A patent/CN106540143A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103394067A (en) * | 2013-03-11 | 2013-11-20 | 肖鸣春 | Cancer treating pharmaceutical composition and preparation method thereof |
| CN104043057A (en) * | 2014-06-28 | 2014-09-17 | 王星月 | Traditional Chinese medicinal composition for treating lymph cancer |
| CN104173835A (en) * | 2014-09-03 | 2014-12-03 | 四川金堂海纳生物医药技术研究所 | Oral medicine for treating lymphangioma and preparation method of oral medicine |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103721131B (en) | A kind of Chinese medicine suppository and its preparation method treating women's chronic pelvic inflammatory disease | |
| CN102038758B (en) | Rheumatism preparation used for treating rheumatism | |
| CN101332277A (en) | Preparation method of emergency liquor for raising the whole blood | |
| CN103861079B (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN101002847A (en) | Medicine for treating mazoplasia, and its preparing method | |
| CN102008650B (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN102861284B (en) | Traditional Chinese medicine compound preparation for treating non-small cell lung cancer and preparation method thereof | |
| CN103536826B (en) | One is treated colpitic Chinese medicine composition and preparation method thereof | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN102671135A (en) | Chinese medicinal composition for treating ovarian cyst, and preparation method thereof | |
| CN104906465A (en) | Traditional Chinese medicine blood-stasis dispersing composition for treating woman chronic pelvic inflammation and preparation method thereof | |
| CN102133366B (en) | Traditional Chinese medicine composition for treating infant acute bacillary dysentery | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| WO2018171672A1 (en) | Anti-cancer pharmaceutical composition and use thereof | |
| CN104082743A (en) | Healthcare food for curing acute gouty arthritis and preparation method thereof | |
| CN106540143A (en) | A kind of pharmaceutical composition and purposes for treating lymphatic cancer | |
| CN104172418A (en) | Vinegar beverage for treating urinary calculus and preparation method thereof | |
| CN103893700A (en) | Chinese medicinal composition for treating breast cancer | |
| CN103735847B (en) | A kind of medicine and preparation method for the treatment of eczema | |
| CN105106713A (en) | Traditional Chinese medicine preparation for treating chronic aplastic anemia | |
| CN104689246B (en) | A kind of medicine for the treatment of gastric cancer | |
| CN104666582B (en) | A kind of health products preparation method and corresponding health products for strengthen immunity | |
| CN104666922A (en) | Chinese medicinal composition for treating irregular menstruation due to deficiency of qi in spleen and kidney | |
| CN104398704A (en) | Traditional Chinese medicine composition for treating stomach cancer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170329 |
|
| RJ01 | Rejection of invention patent application after publication |